01545nas a2200205   4500000000100000008004100001260001200042653001100054653001900065653001200084100001500096700001300111700001300124245007900137856006700216300000900283490000700292520102600299022001401325       2024                            d  bMDPI AG10aChagas10aNew treatments10avaccine1 aFarani PSG1 aJones KM1 aPoveda C00aTreatments and the Perspectives of Developing a Vaccine for Chagas Disease  uhttps://www.mdpi.com/2076-393X/12/8/870/pdf?version=1722505727  a1-200 v123 a<jats:p>Chagas disease (CD) treatment and vaccine development are critical due to the significant health burden caused by the disease, especially in Latin America. Current treatments include benznidazole and nifurtimox, which are most effective in the acute phase of the disease but less so in the chronic phase, often with significant side effects. Here, using the available literature, we summarize the progress in vaccine development and new treatments that promise to reduce CD incidence and improve the quality of life for those at risk, particularly in endemic regions. New treatment options, such as posaconazole and fexinidazole, are being explored to improve efficacy and reduce adverse effects. Vaccine development for CD remains a high priority. The complex life stages and genetic diversity of Trypanosoma cruzi present challenges, but several promising vaccine candidates are under investigation. These efforts focus on stimulating a protective immune response through various innovative approaches.</jats:p>  a2076-393X